A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis

Ibrexafungerp (IBX) (formerly SCY-078) is a novel glucan synthase inhibitor whose oral availability is being evaluated for efficacy against vulvovaginal candidiasis (VVC). Bioavailability and in vitro activity are important efficacy indicators, but accepted susceptibility methods do not always accur...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Larkin, E. L., Long, L., Isham, N., Borroto-Esoda, K., Barat, S., Angulo, D., Wring, S., Ghannoum, M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2019
Assuntos:
Clinical Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496072/
https://ncbi.nlm.nih.gov/pubmed/30885896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02611-18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados